NICE OK For BMS's Opdivo To Shake Up UK RCC Market, Bad News For Pfizer
Executive Summary
Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.